ONLINE PRESS ROOM: NC-002 TRIAL LAUNCH
PRESS RELEASE TB Alliance Launches Combination Drug Trial, Establishes New Pathway to TB and MDR-TB Treatment VIDEO Christine Lubinski Introduction […]
PRESS RELEASE TB Alliance Launches Combination Drug Trial, Establishes New Pathway to TB and MDR-TB Treatment VIDEO Christine Lubinski Introduction […]
The TB Alliance and other organizations spearheading the research and development of new and improved tools to treat, diagnose, and
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded a grant to the TB Alliance as a member
TB Alliance announces the appointment of David Greeley as Senior Vice President, External Affairs. Mr. Greeley will be responsible for
Dr. Tim McHugh Director University College London (UCL) Centre for Clinical Microbiology – REMox TB UCL Lead The microbiology laboratory
Dr Jane Rahedi Ong’ang’o Community Engagement Coordinator Kenya Medical Research Institute (KEMRI), Nairobi, Kenya In January 2010, the Phase III
Dr Stephen H. Gillespie MD DSc Sir James Black Professor of Medicine University of St Andrews University Chief Investigator For
Dr. Martin Springsklee Vice President – Head Global Medical Affairs Anti-Infectives at Bayer HealthCare We started our partnership with the
The TB Alliance and its partners have completed patient enrollment in REMox TB, a global Phase III clinical trial, which
Prof. Charles Mgone Executive Director of the European and Developing Countries Clinical Trials Partnership (EDCTP) The enrolment of volunteers in